Comparative Pharmacology
Head-to-head clinical analysis: DIDRONEL versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIDRONEL versus FOSAMAX PLUS D.
DIDRONEL vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, reducing osteoclast activity and inducing osteoclast apoptosis.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
For Paget disease: 5 mg/kg orally once daily for 6 months, or 5 mg/kg orally once daily for 3 months if retreatment; for heterotopic ossification: 20 mg/kg orally once daily for 2 weeks pre- and 3 months post-surgery; for hypercalcemia of malignancy: 5-10 mg/kg orally once daily for up to 6 months.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal elimination half-life ranges from hours to weeks; initial phase 2-6 hours, deep bone phase up to several weeks due to slow release from bone.
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Renal: 50% unchanged; fecal/biliary: negligible; absorbed drug not excreted renally is retained in bone with slow release.
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate